HOUSTON, TX – Pharm-Olam International LLC, an award-winning, multinational, full-service Clinical Research Organization (CRO) serving the biopharmaceutical and medical device industries, today announced the company has been selected as a winner in Life Science Leader magazine’s 2017 CRO Leadership Awards.
Pharm-Olam was selected as a winner for the second consecutive year in five award categories—Capabilities, Compatibility, Expertise, Quality, and Reliability. Pharm-Olam was also named a Top Performer in three Individual Attribute Awards for Data Quality, Operational Excellence and Responsiveness. In addition, Pharm-Olam was recognized as having Exceeded Customer Expectations in the other three performance-related categories: Meeting Project Timelines, Offering Innovative Solutions, and Providing Technology for Data Access.
“It is an honor to be a back-to-back winner of [the CRO Leadership] awards,” said David L. Grange, CEO, Pharm-Olam International. “The Pharm-Olam team has earned a reputation for performance and ‘wowing’ our clients. These awards confirm that our team continues to impress with their hard and important work. I am incredibly proud of everyone here.”
Each year, Life Science Leader magazine publishes the CRO Leadership Awards based on the results of market research conducted by Industry Standard Research (ISR). This year, via online survey, ISR evaluated 72 CROs against 27 different performance metrics. The survey respondents were from biopharmaceutical companies of all sizes and market caps. Respondents were required to have worked on an outsourced study within the past 18 months.
Pharm-Olam operates in more than 60 countries worldwide, offering end-to-end clinical trial support for Phase I-IV clinical trials. More information about Pharm-Olam and its full-service capabilities and offerings are available at www.Pharm-Olam.com, or by request via email email@example.com (link sends e-mail).
About Pharm-Olam International
Pharm-Olam International is a global contract research company with a presence in over 40 countries, offering a wide range of comprehensive, clinical research services to the pharmaceutical, biotechnology, and medical device industries. From Phase I to Phase IV, Pharm-Olam focuses on delivering the highest quality data, achieving targeted enrollment, and meeting projected timelines.